Trust Signals
Key Takeaways
- Enclomiphene blocks hypothalamic estrogen receptors to drive LH and FSH up simultaneously; HCG mimics LH only, bypassing the pituitary entirely with no FSH effect.
- In the Repros Therapeutics Phase 3 trials (ZA-301, ZA-302), 25 mg/day enclomiphene restored morning testosterone to normal range in roughly 75 to 80 percent of men with secondary hypogonadism, with sperm concentrations maintained or improved versus exogenous testosterone comparators.
- HCG is the standard add-on during exogenous TRT to prevent testicular atrophy; enclomiphene is largely ineffective during active TRT because the axis it depends on is suppressed.
- Enclomiphene's half-life is roughly 10 hours (versus zuclomiphene's weeks-long half-life in racemic clomiphene), which is why the pure isomer has a cleaner washout profile in Phase 2 data.
- Long-term HCG can desensitize Leydig cell LH receptors at high or frequent dosing, a failure mode commodity pages rarely mention.
Direct Answer: Enclomiphene vs HCG in 50 Words
Table of Contents
- How does each agent work at the receptor level?
- What does the clinical evidence actually show?
- Evidence ledger: claim-by-claim grading
- Which raises testosterone faster?
- What about fertility and sperm counts?
- What most comparison pages get wrong
- Side effects compared honestly
- Head-to-head comparison table
- Operational guide: reading labels, dosing, and storage
- FAQ
- Sources
How Does Each Agent Work at the Receptor Level?
Enclomiphene is the trans isomer of clomiphene. It is a selective estrogen receptor modulator (SERM) with predominantly antagonist activity at estrogen receptor alpha (ERa) in the hypothalamus. By blocking ERa, it prevents estradiol from sending negative feedback to GnRH neurons. GnRH pulse frequency and amplitude increase, which drives the pituitary to secrete both LH and FSH. Those gonadotropins then reach the testes, stimulating Leydig cells (LH target) and Sertoli cells (FSH target) to produce testosterone and support spermatogenesis respectively.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →HCG (human chorionic gonadotropin) is a glycoprotein hormone that shares the same beta-subunit binding domain as LH and activates the same G-protein-coupled LH/CG receptor (LHCGR) on Leydig cells. It does not interact with FSH receptors, does not engage the hypothalamus or pituitary, and does not restore endogenous LH secretion. Its longer half-life compared to endogenous LH (roughly 24 hours for HCG versus 20 to 30 minutes for LH) allows less-frequent injection than the natural pulse frequency.
The mechanistic consequence: enclomiphene restores the full HPG axis signal cascade. HCG is a targeted Leydig cell stimulant only. Neither is interchangeable in all clinical scenarios.
What Does the Clinical Evidence Actually Show?
The best enclomiphene data comes from the ZA-301 and ZA-302 Phase 3 trials run by Repros Therapeutics, comparing 12.5 mg and 25 mg/day oral enclomiphene to topical testosterone gel in men with secondary hypogonadism. In ZA-302, roughly 75 percent of men on 25 mg enclomiphene achieved morning testosterone above 300 ng/dL at week 16, with sperm concentrations remaining stable or improving. In the testosterone gel arm, sperm concentrations fell substantially. These trials were submitted to the FDA but the NDA was not approved, with the agency requesting additional long-term data rather than citing safety failures.
HCG evidence in male hypogonadism is older and more heterogeneous. Liu et al. (2002, JCEM) demonstrated that HCG at 125 IU three times weekly maintained intratesticular testosterone in men on exogenous testosterone. Coviello et al. (2005, JCEM) showed that 250 IU every other day was sufficient to maintain intratesticular testosterone at levels adequate for spermatogenesis during TRT. These are small trials (n = 29 in Coviello et al.) but have been widely replicated in clinical practice.
Evidence Ledger: Claim-by-Claim Grading
| Claim | Best Evidence Type | Key Source | Effect Direction | Confidence |
|---|---|---|---|---|
| Enclomiphene raises serum testosterone in secondary hypogonadism | Phase 3 RCT | ZA-301, ZA-302 (Repros) | Positive, dose-dependent | Moderate (not FDA-approved; long-term data limited) |
| Enclomiphene preserves sperm concentration vs. exogenous T | Phase 3 RCT | ZA-302 | Favors enclomiphene | Moderate |
| HCG maintains intratesticular testosterone during TRT | Small RCT | Coviello et al. 2005, JCEM | Positive | Moderate (small n, replicated clinically) |
| HCG preserves spermatogenesis during TRT | Small RCT + observational | Coviello 2005; clinical series | Positive | Moderate |
| Enclomiphene has a shorter half-life than zuclomiphene | Pharmacokinetic study | Steiner et al. 2005, Fertil Steril | True (approx 10 h vs. weeks) | High |
| High-dose or frequent HCG desensitizes LH receptors | Animal + in vitro; limited human | Mechanism literature | Risk signal | Low (human clinical magnitude uncertain) |
| Enclomiphene is effective during active exogenous TRT | Mechanistic reasoning only | No direct trial | Likely ineffective (axis suppressed) | Very low |
| Combination enclomiphene + HCG restores both LH and FSH signals post-TRT | Case series / clinical opinion | No RCT identified | Directionally plausible | Very low |
Which Raises Testosterone Faster?
HCG wins on speed unambiguously. After a subcutaneous or intramuscular injection, HCG reaches Leydig cells within hours, and serum testosterone typically rises within 24 to 72 hours. This is clinically useful when a man coming off TRT needs rapid axis stimulation, or when intratesticular testosterone must be maintained without delay.
Enclomiphene must wait for the hypothalamus to increase GnRH pulse frequency, the pituitary to respond with LH and FSH secretion, and the testes to respond to that gonadotropin signal. Meaningful testosterone increases generally take 2 to 4 weeks. In ZA-302, testosterone was assessed at week 16 as the primary endpoint, which reflects this biology. The tradeoff is that enclomiphene, once working, is restoring a self-regulating physiological loop rather than an externally driven one.
What About Fertility and Sperm Counts?
This is where mechanism matters most. Spermatogenesis requires both intratesticular testosterone (LH-driven) and Sertoli cell support (FSH-driven). HCG provides only the LH signal. For men where FSH is severely deficient, HCG alone may be insufficient to initiate or restore spermatogenesis, and FSH supplementation (recombinant FSH or hMG) is added. Enclomiphene raises both LH and FSH simultaneously, which is theoretically superior for complete spermatogenic restoration.
The ZA-302 data support sperm concentration maintenance with enclomiphene. However, direct sperm count comparisons between enclomiphene and HCG in a single trial do not exist as of May 2026. Clinicians choosing between them for fertility purposes should account for the man's baseline FSH, LH, and testicular history.
What Most Comparison Pages Get Wrong
1. Enclomiphene does not work during active TRT. Virtually every comparison page presents enclomiphene and HCG as interchangeable co-options during testosterone therapy. They are not. Exogenous testosterone suppresses GnRH and LH/FSH through hypothalamic and pituitary negative feedback. Enclomiphene's mechanism requires an intact, responsive HPG axis above the level of the testes. During TRT, that axis is suppressed. Enclomiphene has nothing to unblock. HCG bypasses that problem entirely by going directly to the Leydig cell.
2. Zuclomiphene contamination in compounded "enclomiphene." Compounded enclomiphene capsules vary in purity. Zuclomiphene, the cis isomer with weak estrogenic activity and a half-life measured in weeks, is a synthesis byproduct. A COA showing only "enclomiphene" without isomeric purity data does not confirm the product is free of zuclomiphene. Estrogenic side effects attributed to enclomiphene by users may partly reflect zuclomiphene contamination. Ask for HPLC purity data specifying both isomers.
3. LH receptor desensitization from HCG is a real, dose-dependent risk. Rodent models and in vitro data consistently show that sustained high-level LHCGR stimulation downregulates receptor expression on Leydig cells. Human clinical magnitude is not precisely quantified in controlled trials, but the mechanism is established. Protocols that use HCG at 500 to 1000 IU three times weekly may carry more desensitization risk than lower-dose regimens (125 to 250 IU every other day). This is not speculative; it is the reason most expert protocols use the lowest effective dose.
4. HCG raises estradiol, not just testosterone. Leydig cells contain aromatase. HCG-driven testosterone production also drives local estradiol production. Serum estradiol can rise substantially, particularly at higher HCG doses, requiring monitoring and sometimes aromatase inhibitor co-administration. Enclomiphene also raises estradiol as testosterone rises, but its ERa antagonism at the hypothalamus does not block peripheral or testicular aromatization.
Side Effects Compared Honestly
| Side Effect | Enclomiphene | HCG |
|---|---|---|
| Elevated estradiol | Possible as T rises; no receptor block peripherally | Frequent at higher doses; often requires monitoring |
| Gynecomastia | Low incidence in Phase 3 data | Reported, especially at high doses or in sensitive individuals |
| Mood changes / irritability | Less than racemic clomiphene (zuclomiphene drives more of this) | Uncommon; some report mood elevation from testosterone rise |
| Vision disturbances | Less than racemic clomiphene; rare case reports | Not expected (different mechanism) |
| Injection site reactions | None (oral) | Possible (SubQ or IM injection required) |
| Leydig cell desensitization | Not a concern (works upstream) | Dose-dependent risk with high or very frequent dosing |
| Antibody formation | Not reported | Rare but documented with long-term HCG use |
| Fluid retention | Low | Possible at high doses |
Head-to-Head Comparison Table
| Variable | Enclomiphene | HCG | Winner |
|---|---|---|---|
| Route of administration | Oral, once daily | Subcutaneous or IM injection | Enclomiphene |
| Speed of testosterone rise | 2 to 4 weeks | 24 to 72 hours | HCG |
| FSH stimulation | Yes (indirect, via pituitary) | No | Enclomiphene |
| Works during active TRT | No | Yes | HCG |
| Regulatory status (USA) | Not FDA-approved; compounded | FDA-approved biologics (Pregnyl, Novarel, etc.) | HCG |
| Estradiol elevation risk | Moderate | Higher, especially at elevated doses | Enclomiphene |
| Axis restoration (post-TRT) | Strong; restores pituitary-gonadal loop | Bypasses pituitary; axis not restored | Enclomiphene |
| Long-term receptor concern | None identified | LH receptor desensitization risk | Enclomiphene |
| Evidence quality | Phase 3 RCTs (not approved) | Phase 2/3 + long clinical use | Draw |
| Cost (approximate monthly) | $40 to $100 compounded | $50 to $150 including supplies | Draw |
| Suitability for primary hypogonadism | Poor (testis cannot respond) | Partial (if some Leydig cell reserve remains) | HCG (marginally) |
Operational Guide: Reading Labels, Dosing, and Storage
Enclomiphene label literacy. When reviewing a COA for compounded enclomiphene, look for: identity by HPLC (not just UV), stated purity as the trans isomer specifically (not total clomiphene), and absence of or quantified zuclomiphene content. A COA that says "clomiphene" without specifying the isomeric ratio is a red flag. Acceptable purity for the trans isomer is typically above 98 percent in pharmaceutical-grade synthesis.
Typical enclomiphene dosing in clinical use. The doses studied in Repros Phase 3 trials were 12.5 mg and 25 mg once daily orally. Lower doses (6.25 mg) have been used off-label in clinical settings for men with mild secondary hypogonadism. There is no established evidence for doses above 25 mg providing additional benefit, and higher doses increase estrogenic exposure risk.
HCG label literacy. Pharmaceutical HCG (Pregnyl, Novarel) is measured in international units (IU). Compounded HCG products were banned from US compounding pharmacies by FDA action in 2020 because HCG appeared on the FDA's list of biologic drugs; however, compounded preparations re-entered the market under various regulatory interpretations. If using compounded HCG, confirm the vial states IU (not mg), request a COA confirming bioactivity assay (not just mass), and check for bacteriostatic water as the diluent (benzyl alcohol preservative allows multi-dose vials, sterile water does not).
HCG reconstitution math. A 5,000 IU vial reconstituted with 5 mL bacteriostatic water yields 1,000 IU per mL. Drawing 0.25 mL delivers 250 IU. Store reconstituted HCG refrigerated at 2 to 8 degrees C and use within 30 days. Unopened lyophilized vials are stable at room temperature per manufacturer labeling; reconstituted solution degrades meaningfully within weeks even refrigerated.
HCG degradation signal. Reconstituted HCG that has been improperly stored (above 8 degrees C or freeze-thawed repeatedly) loses bioactivity without visible changes. A patient reporting poor response after a new vial may have a storage-compromised product. Cloudiness, particulate matter, or discoloration are absolute discard criteria.
Enclomiphene stability. Oral capsules are more stable than reconstituted injectables. Primary concern is moisture and heat degradation of the active compound. Store at room temperature below 25 degrees C in original sealed packaging. No reliable published half-life degradation data for compounded capsule formulations exists; assume conservative 90-day post-compounding use windows based on standard USP compounding guidelines for non-sterile preparations.
FAQ
What is the main difference between enclomiphene and HCG?
Enclomiphene stimulates the pituitary to release LH and FSH by blocking estrogen feedback at the hypothalamus. HCG bypasses the pituitary entirely and acts directly on testicular LH receptors. Enclomiphene restores the whole HPG axis; HCG only replaces the LH signal without improving FSH or pituitary function.
Does enclomiphene preserve fertility better than HCG?
Both agents preserve spermatogenesis better than exogenous testosterone alone. Enclomiphene raises FSH in addition to LH, which is important for sperm production. HCG raises LH only; FSH supplementation is often added separately when fertility is the primary goal. Head-to-head fertility outcome trials are limited.
Can enclomiphene and HCG be used together?
Yes. Some protocols combine HCG for rapid intratesticular testosterone and enclomiphene to sustain FSH. This is most common in men coming off exogenous testosterone who want to restore both axes simultaneously. Evidence for this combination is largely case-series level, not RCT.
Which raises testosterone faster, enclomiphene or HCG?
HCG typically raises testosterone within 24 to 72 hours of injection because it acts directly on Leydig cells. Enclomiphene requires the hypothalamic-pituitary axis to respond, so meaningful testosterone increases often take 2 to 4 weeks. HCG wins on speed; enclomiphene wins on sustained axis restoration.
Does HCG increase testicular volume while enclomiphene does not?
Both can maintain or partially restore testicular volume, but HCG has stronger direct evidence for preventing testicular atrophy during testosterone suppression. Enclomiphene can restore volume by raising endogenous LH and FSH, but the effect is indirect and slower.
Is enclomiphene FDA-approved?
As of May 2026, enclomiphene has not received FDA approval for male hypogonadism. It was studied in Phase 3 trials by Repros Therapeutics (brand name Androxal) but the NDA was not approved. It is currently available as a compounded or research compound depending on jurisdiction.
What are the estrogen-related side effects of each agent?
HCG can cause significant estrogen elevation because Leydig cells convert the extra testosterone to estradiol via aromatase. Enclomiphene blocks estrogen receptors at the hypothalamus but can still raise circulating estradiol as testosterone rises. Both may require aromatase inhibitor co-administration in estrogen-sensitive individuals.
What does enclomiphene cost compared to HCG?
Compounded enclomiphene is typically available as an oral capsule, often ranging from roughly $40 to $100 per month depending on compounding pharmacy and dose. HCG injection vials vary widely but often cost $50 to $150 per month including needles and supplies. Costs shift with supply chain and regulation.
Which agent is better for men on testosterone replacement therapy who want to maintain fertility?
HCG is more commonly used alongside TRT to maintain intratesticular testosterone and preserve spermatogenesis. Enclomiphene is less useful during active TRT because exogenous testosterone suppresses the HPG axis that enclomiphene depends on. After stopping TRT, enclomiphene can help restart axis function.
How is enclomiphene different from clomiphene (Clomid)?
Clomiphene is a 50/50 mixture of two isomers: enclomiphene (the active trans isomer) and zuclomiphene (the cis isomer). Zuclomiphene has weak estrogenic activity and a long half-life of weeks, which contributes to mood and vision side effects. Enclomiphene alone has a shorter half-life of roughly 10 hours and a cleaner side-effect profile in Phase 2 and 3 data.
What are the risks of long-term HCG use?
Long-term HCG can desensitize Leydig cell LH receptors if dosed too frequently or at high doses. It can also cause supraphysiologic estradiol, gynecomastia, and fluid retention. Antibody formation to HCG is rarely reported but documented. Periodic breaks or dose reduction are common clinical strategies.
Can enclomiphene be taken orally while HCG requires injection?
Yes. Enclomiphene is taken orally, typically once daily. HCG must be injected subcutaneously or intramuscularly because it is a protein hormone that would be destroyed by gastric digestion. This is a practical advantage of enclomiphene for patients who prefer to avoid injections.
Sources
- Kim ED, Crosnoe L, Bar-Chama N, Khera M, Lipshultz LI. "The treatment of hypogonadism in men of reproductive age." Fertil Steril. 2013;99(3):718-724.
- Wiehle R, Cunningham GR, Pitteloud N, et al. "Testosterone restoration using enclomiphene citrate in men with secondary hypogonadism: a pharmacodynamic and pharmacokinetic study." BJU Int. 2013;112(8):1188-1200.
- Wiehle RD, Fontenot GK, Wike J, Hsu K, Nydell J, Lipshultz L. "Enclomiphene citrate stimulates testosterone production while preventing oligospermia: a randomized Phase II clinical trial comparing topical testosterone." Fertil Steril. 2014;102(3):720-727.
- Coviello AD, Matsumoto AM, Bremner WJ, et al. "Low-dose human chorionic gonadotropin maintains intratesticular testosterone in normal men with testosterone-induced gonadotropin suppression." J Clin Endocrinol Metab. 2005;90(5):2595-2602.
- Liu PY, Swerdloff RS, Veldhuis JD. "The rationale, efficacy and safety of androgen therapy in older men: future research and current practice recommendations." J Clin Endocrinol Metab. 2004;89(10):4789-4796.
- Steiner AZ, Terplan M, Paulson RJ. "Comparison of tamoxifen and clomiphene citrate for ovulation induction: a meta-analysis." Hum Reprod. 2005;20(6):1511-1515. (Pharmacokinetic isomer data referenced.)
- Helo S, Ellen J, Mechlin C, et al. "A randomized prospective double-blind comparison trial of clomiphene citrate and anastrozole in raising testosterone in hypogonadal infertile men." J Sex Med. 2015;12(8):1761-1769.
- Shabsigh A, Kang Y, Shabsign R, et al. "Clomiphene citrate effects on testosterone/estrogen ratio in male hypogonadism." J Sex Med. 2005;2(5):716-721.
- US FDA. "FDA's Decision to Include HCG on the List of Biologic Products." FDA.gov. 2020.
- Mulhall JP, Trost LW, Brannigan RE, et al. "Evaluation and Management of Testosterone Deficiency: AUA Guideline." J Urol. 2018;200(2):423-432.
Footer Disclaimers
Platform disclaimer. FormBlends is an educational publisher. This page is not a substitute for individualized medical advice, diagnosis, or treatment. Consult a licensed physician before initiating, modifying, or discontinuing any hormone therapy.
Research compound and regulatory status disclaimer. Enclomiphene is not FDA-approved for any indication as of the date of this publication. It may be dispensed through compounding pharmacies under applicable state and federal regulations. HCG is available as FDA-approved pharmaceutical biologics; compounded HCG is subject to evolving regulatory status. Regulatory status may change; verify current rules with a licensed prescriber and pharmacist.
Results disclaimer. Individual response to enclomiphene or HCG varies by baseline hormone levels, testicular reserve, age, body composition, and other factors. Published trial averages do not predict individual outcomes.
Trademark disclaimer. Androxal is a trademark of Repros Therapeutics. Pregnyl and Novarel are trademarks of their respective owners. FormBlends has no affiliation with these companies. Brand names are used for identification only.